The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication

Eye

Volumn 19, Issue 1, 2005, Pages 41-44

  Best, J L ^a,b   Acheson, James F ^a,b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Drug reactions; Vigabatrin; Visual field defects

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EPILEPSY; FOLLOW UP; HUMAN; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; PATIENT ATTITUDE; PERIMETRY; SEIZURE; STUDENT T TEST; VISUAL FIELD; VISUAL FIELD DEFECT;

EID: 13244260754     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6701405     Document Type: Article

References (17)

1. Ben-Menachem E. Vigabatrin. Epilepsia 1995; 36: S95-S104.
2. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systemic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-880.
3. Nousianen, Mantyjarvi M, Kalviainen R. No reversion in vigabatrin-associated field defects. Neurology 2001; 57: 1916-1917.
4. Wild JM, Martinez C, Reinshagen G, Harding G. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40(12): 1784-1794.
5. Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainer E, Pastaner J, Pastaner K et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53 922-926.
6. Lawden MC, Eke T, Degg C, Harding GFA, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67: 716-722.
7. Newman WD, Tocher K, Acheson J. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 2002; 16: 567-571.
8. Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000; 55: 40-45.
9. Krakow K, Polizzi G, Riordan-Eva P, Holder G, MacLeod WN, Fish DR. Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 2000; 9: 287-290.
10. Giordano L, Valseriati D, Vignoli A, Morescalchi F, Gandolfo E. Another case of reversibility of visual field defects induced by vigabatrin monotherapy: is young age a favourable factor? Neurol Sci 2000; 21: 185-186.
11. Kraemer G, Ried S, Landau K, Harding GFA. Vigabatrin. Reversibility of severe concentric visual field defects after early detection and drug withdrawal:a case report. Epilepsia 2000; 41 Suppl): 144.
12. Van Der Torren Kors, Graniewski-Wijnands HS, Polak BCP. Visual field and electrophysiological abnormalities due to vigabatrin. Documenta. Ophthalmologica 2002; 104: 181-188.
13. Coupland SG, Zackro DH, Leonard BC, Ross TM. Vigabatrin effect on inner retinal function. Ophthalmology 2001; 108: 1493-1496.
14. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 180-181.
15. Wilson EA, Brodie MJ, Wong IC, Mawer GE, Sander JWAS, Blackwell N et al. Severe persistent visual field constriction associated with vigabatrin (multiple letters). BMJ 1997; 314: 1693-1695.
16. Harding HFA, Mackenzie R, Klistorner A. Severe persistent visual field constriction associated with vigabatrin. BMJ 1998; 316: 232-233.
17. Paul SR, Krauss GL, Miller NR, Medura M, Miller TA, Johnson MA et al. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia 2001; 42: 525-530.